HIF1A and neoplasm: Since hypoxia and ROS are the main drivers in immune exhaustion, ROS-responsive manganese dioxide (MnO2) NPs are developed to carry the HIF-1α inhibitor (acriflavine) to the tumor sites, successfully relieving T-cell exhaustion and activating tumor-specific immune responses [171].